Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
Carcinoma, Hepatocellular, Hepatitis, Viral, Human
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer…
- Trial name
- Lipiocis (NCT00116454)
- Testing
- 131 I-lipiodol
- Where
- France
- Volunteers
- 73 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
This multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1…
- Trial name
- NCT02212379
- Testing
- raltegravir and etravirine
- Where
- 19 sites in France, Spain
- Volunteers
- 170 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV INFECTION
Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
Phase II trial assessing the efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse…
- Trial name
- DARULIGHT (NCT02384967)
- Testing
- Darunavir
- Where
- France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Chronic, HIV Infection
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
This phase II, multicentric, national pilot trial is designed to estimate the sustained virological response rate (SVR) following a 12 weeks treatment by telaprevir combined with a 48 or 72 weeks treatment by peginterferon and…
- Trial name
- TelapreVIH (NCT01332955)
- Testing
- Telaprevir, pegIFN alfa-2a, Ribavirin
- Where
- France
- Volunteers
- 70 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Immunodeficiency Virus, Lipohypertrophy
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Evaluation of antiretroviral therapy combining Raltegravir and Maraviroc in patients with virological success, presenting with clinical lipohypertrophy.
- Trial name
- ROCnRAL (NCT01420523)
- Testing
- Raltegravir-Maraviroc
- Where
- France
- Volunteers
- 48 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-2 Infection
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
The HIV-2 is less common ie 1-2 million people in West Africa. HIV-2 does have the same sensitivity to antiretroviral treatment (ART) compared to HIV-1.
- Trial name
- VIH-2 (NCT01605890)
- Testing
- emtricitabine / tenofovir disoproxil fumarate / raltegravir .
- Where
- France
- Volunteers
- 30 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, HBV Infection
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
The VIROPREG study is a French prospective multicenter cohort study that aims to assess the impact of viral infections and antiviral treatments received during pregnancy on maternal and child health.
- Conditions
- HIV Infection, HBV Infection, HDV Infection, HCV Infection
- Trial name
- VIROPREG (NCT07412977)
- Testing
- Blood sampling, Umbilical cord blood sampling, Survey using a questionnaire
- Where
- France
- Volunteers
- 5,160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Ebola virus disease (EVD) is emerging regularly in various African countries for various reasons: during contact with mortal remains, during an unsafe burial or following the viral dissemination around a recovered patient.
- Trial name
- NCT05202288
- Testing
- Ervebo, Inmazeb
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
EBOla Post-Exposure Prophylaxis
EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
- Trial name
- EBO-PEP (NCT06841614)
- Testing
- Ervebo, Inmazeb
- Where
- 4 sites in Democratic Republic of the Congo, Guinea and 2 more
- Volunteers
- 160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, HIV-1-infection
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults…
- Conditions
- Tuberculosis, HIV-1-infection, Immuno-Deficiency
- Trial name
- DATURA (NCT04738812)
- Testing
- Intensified TB treatment (initial phase), WHO standard TB treatment (initial phase)
- Where
- 6 sites in Cambodia, Cameroon and 4 more
- Volunteers
- 1,330 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy
Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
This Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers.
- Trial name
- MUCOBOOST (NCT06821126)
- Testing
- LVT-001, Cormirnaty
- Where
- 5 sites in France
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis, HIV I Infection
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis…
- Trial name
- TIMPANI (NCT05590455)
- Testing
- Adalimumab Injection
- Where
- 3 sites in Brazil, Mozambique and 1 more
- Volunteers
- 130 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV Infection
Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia
The goal of this clinical trial is to evaluate the effectiveness of sofosbuvir/daclatasvir combination for children aged ≥ 6 years old and adolescents with active HCV infection in Cambodia
- Trial name
- HEPEDIAC (NCT05992077)
- Testing
- Sofosbuvir/Daclatasvir
- Where
- 4 sites in Cambodia
- Volunteers
- 21,000 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HPV Infection, Anal Cancer
Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial.
- Trial name
- HPVsign (NCT06522256)
- Testing
- High-resolution anoscopy
- Where
- 3 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Cardiovascular Diseases
Implementation and Effectiveness of Physical Activity to Prevent Disability in HIV-infected Adults Older Than 50 From Côte d'Ivoire
The overall objective of this research is to provide evidence on the effectiveness and implementation of two strategies deliver a structured programme of physical activity (PA) people living with HIV older than 50 years from…
- Conditions
- HIV Infections, Cardiovascular Diseases, Insulin Resistance Syndrome X
- Trial name
- VIRAGE+ (NCT06139497)
- Testing
- Physical activity programme, Home-based physical activity
- Where
- 2 sites in Côte d’Ivoire
- Volunteers
- 180 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Japanese Encephalitis
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
The primary objective of this study is to quantify the clinical burden of Japanese Encephalitis (JE) and the asymptomatic circulation of JEV among Cambodian children, through two pediatric cohorts: non-febrile children at…
- Trial name
- DEMELE-JEV (NCT06674837)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV, Substance Use Disorders
Community Intervention to Eliminate HCV Among People Who Use Drugs.
The goal of this interventional study is twofold with the evaluation of the feasibility and potential usefulness of an implementation strategy, and the efficiency of a community-based model of mass screening and immediate…
- Trial name
- ICONE2 (NCT05794646)
- Testing
- Hybrid effectiveness-implementation study type 2
- Where
- 4 sites in France, Martinique
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C Virus Infection
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
Hepatitis C is a common and potentially serious disease. However, there are treatments that can cure it. That's why it's so important to detect the hepatitis C virus (HCV) and treat those affected.
- Trial name
- ACCESS+ (NCT07098481)
- Testing
- ACCESS+ strategy Epclusa 400/100 Oral Tablet, ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet, Standard Strategy Vosevi 400/100/100 Oral Tablet
- Volunteers
- 576 people
- Sponsor
- ANRS, Emerging Infectious Diseases